210 related articles for article (PubMed ID: 18474663)
1. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
[No Abstract] [Full Text] [Related]
2. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
3. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
Montagna GL; Malesci D; Buono R; Valentini G
Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
[No Abstract] [Full Text] [Related]
4. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
5. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
6. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
[No Abstract] [Full Text] [Related]
7. Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
Hakimi S; Rivière S; Del Giudice P; Dereure J; Le Quellec A
Dermatology; 2010; 220(1):63-5. PubMed ID: 19907139
[TBL] [Abstract][Full Text] [Related]
8. Tuberculous peritonitis.
Finlay DG; Szauter K; Raju GS; Snyder N
Am J Gastroenterol; 2005 Jul; 100(7):1624-5. PubMed ID: 15984997
[No Abstract] [Full Text] [Related]
9. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
[No Abstract] [Full Text] [Related]
10. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
Hernández MV; Ruiz-Esquide V; Gómez-Caballero ME; Gómez-Puerta JA; Cañete JD; Sanmartí R
Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
[No Abstract] [Full Text] [Related]
11. Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of infliximab in a patient with ankylosing spondylitis.
Miki H; Okamoto A; Ishigaki K; Sasaki O; Sumitomo S; Fujio K; Yamamoto K
J Rheumatol; 2011 Jun; 38(6):1220. PubMed ID: 21632692
[No Abstract] [Full Text] [Related]
12. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
13. TNF inhibitors for ankylosing spondylitis in the real world.
McVeigh CM; Bell AL; Cairns AP
Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
[No Abstract] [Full Text] [Related]
14. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
Goncalves DP; Laurindo I; Scheinberg MA
J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
[No Abstract] [Full Text] [Related]
15. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
16. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
Jois RN; Gaffney K; Keat A
Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
[No Abstract] [Full Text] [Related]
17. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
Temel M; Atagündüz P; Direskeneli H
Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
[No Abstract] [Full Text] [Related]
18. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
[No Abstract] [Full Text] [Related]
19. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
Hermann J; Müller T; Yazdani-Biuki B; Aringer M; Herold M; Ebner W; Ofner P; Graninger W
Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
[No Abstract] [Full Text] [Related]
20. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
Algül A; Basoglu C; Kiralp MZ; Ozçakar L
Acta Reumatol Port; 2008; 33(4):477-8. PubMed ID: 19107094
[No Abstract] [Full Text] [Related]
[Next] [New Search]